Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6470532 | 0.86 | HTT (0.58) | HTTSMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL9342841 | 0.86 | MAPK1 (0.68) | MAPK1PKMHTTSMN1; SMN2NPC1 | |
| SCHEMBL7475639 | 0.86 | SMN1; SMN2 (0.56) | MAPK1HTTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29910262 | 0.84 | PDK1 (0.65) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL22920172 | 0.84 | PDK1 (0.65) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL595191 | 0.84 | FAAH (0.51) | SMN1; SMN2NPC1RAB9ALMNAMEN1 | |
| SCHEMBL3616219 | 0.83 | MAPT (0.57) | MAPK1SMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL7861824 | 0.83 | FAAH (0.50) | SMN1; SMN2NPC1RAB9ALMNAMEN1 | |
| SCHEMBL21768037 | 0.83 | THRB (0.51) | MAPK1PKMHTTSMN1; SMN2NPC1 | |
| SCHEMBL29351023 | 0.83 | MEN1 (0.53) | HTTSMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2410856-A1 | DIAMINOPTERIDINE DERIVATIVES | Biorelix, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110907-A1 | DIAMINOPTERIDINE DERIVATIVES | BIORELIX, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2006044961-A1 | PPAR-GAMMA MODULATORES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283219-A1 | DIAMINOPTERIDINE DERIVATIVES | MPO, AOC1, DCTD | MAPK1 3619/4885PKM 2174/4885HTT 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.